Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Yutaka Niihara

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

Biography

Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, is the founder of Emmaus Life Sciences, Inc., and the principal inventor of Endari, an L-glutamine therapy for treatment of sickle cell disease approved by FDA in July 2017. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium.
Publications

L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β°-Thalassemia Patients at Six Months – A Phase II Randomized Trial

Background: Increased oxidant stress plays an important role in the pathophysiology of sickle cell disease. Nicotinamide Adenine Dinucleotide (NAD) is an important anti-oxidant that protects hemoglobin as demonstrated in diseases such as methemoglobinemia. Early in-vitro studies have shown that L-glutamine, a precursor for NAD, reduced oxidant stre... Read More»

Yutaka Niihara, Henry Macan, James R. Eckman, Han Koh, Melanie L Cooper, Thomas R Ziegler, Rafael Razon, Kouichi R Tanaka, Charles W Stark and Cage S Johnson

Research Article: Clin Pharmacol Biopharm 2014, 3:116

DOI: 10.4172/2167-065X.1000116

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF

Top